Medicinal Plants Used To Treat Sexual Dysfunction- A review

New Drug Approvals

See on Scoop.itNew drug approvals

Medicinal Plants Used To Treat Sexual Dysfunction: A Review   by Ramandeep et al. Int J Recent Adv Pharm Res, 2013;3(1):29-35. ISSN: 2230-9306; www.ijrapronline.com. 29. Medicinal Plants Used To Tr…

See on newdrugapprovals.wordpress.com

View original post

Advertisements

Medicinal Plants Used To Treat Sexual Dysfunction- A review

New Drug Approvals

See on Scoop.itNew drug approvals

Medicinal Plants Used To Treat Sexual Dysfunction: A Review   by Ramandeep et al. Int J Recent Adv Pharm Res, 2013;3(1):29-35. ISSN: 2230-9306; www.ijrapronline.com. 29. Medicinal Plants Used To Tr…

See on newdrugapprovals.wordpress.com

View original post

Adamas claims success with new and improved Parkinson’s drug

New Drug Approvals

amantadine

Adamas claims success with new and improved Parkinson’s drug

Adamas Pharmaceuticals is claiming success with a Phase II/III study of its extended-release version of amantadine for Parkinson’s disease. Investigators say that the lead drug–ADS-5102, reformulated in a way designed to reduce the severity of side effects that plague patients–demonstrated a statistically significant improvement in levodopa-induced dyskinesia when compared with a placebo after 8 weeks of therapy.

Read more: http://www.fiercebiotech.com/story/adamas-claims-success-new-and-improved-parkinson-s-drug/2013-06-18?utm_medium=nl&utm_source=internal

Amantadine (trade name Symmetrel, by Endo Pharmaceuticals) is a drug that has US Food and Drug Administration approval for use both as an antiviral and an antiparkinsonian drug. It is the organic compound 1-adamantylamine or 1-aminoadamantane, meaning it consists of an adamantane backbone that has an amino group substituted at one of the four methyne positions. Rimantadine is a closely related derivative of adamantane with similar biological properties.

Apart from medical uses, this compound is useful as a…

View original post 113 more words

HISTORY OF HOMEOPATHY

New Drug Approvals

The theories and principles of homeopathy have their origins in medicinal traditions established thousands of years ago in Ancient Greece and Rome.

In the 5th century BCE the Greek physician Hippocrates (460–377 BCE) clearly established the idea that disease was the result of natural forces rather than divine intervention, and that patients’ own powers of healing should be encouraged (see page 19). Contemporary medical theories were based upon the Law of Contraries, which advocated treating an illness by prescribing a substance that produced opposite or contrary symptoms. Diarrhea, for example, could be treated by a substance that caused constipation, such as aluminum hydroxide.
In contrast, Hippocrates developed the use of the Law of Similars, based on the principle that “like cures like” (see page 18). This theory proposed that substances capable of causing symptoms of illness in healthy people could also be used to treat similar symptoms during…

View original post 1,574 more words

Tocilizumab Impresses in Polyarticular Juvenile Arthritis

New Drug Approvals

tocilizumab

Tocilizumab Impresses in Polyarticular Juvenile Arthritis
Medscape

MADRID, Spain — Children with polyarticular juvenile idiopathic arthritis treated with tocilizumab (Actemra, Genentech) achieved high response rates with sustained improvement in the phase 3 CHERISH trial.

The results prompted the US Food and Drug Administration toapprove tocilizumab for this indication. The drug is already approved for systemic juvenile idiopathic arthritis and for adults with moderate to severe rheumatoid arthritis.

read all at

http://www.medscape.com/viewarticle/806572

Tocilizumab (INN, or atlizumab, developed by Hoffmann–La Roche and Chugai and sold under the trade names Actemra and RoActemra) is an immunosuppressive drug, mainly for the treatment of rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of RA in children. It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is…

View original post 18 more words

Amgen In Focus

New Drug Approvals

Amgen In Focus
Seeking Alpha
According to Amgen, they have 45 drugs in development from Phase 1 to Phase 3. Conversely, Gilead has 32 drugs in development and Pfizer has 64. Meanwhile, Gilead only has 8 drugs in Phase 3, Pfizer has 25, and Amgen has 14. 7 of those Phase 3 

http://seekingalpha.com/article/1510002-amgen-in-focus?source=google_news

Amgen has the second deepest pipeline of drugs of the three large cap biotechs. According to Amgen, they have 45 drugs in development from Phase 1 to Phase 3. Conversely, Gilead has 32 drugs in development and Pfizer has 64. Meanwhile, Gilead only has 8 drugs in Phase 3, Pfizer has 25, and Amgen has 14. 7 of those Phase 3 drugs are focused on cancer treatments for Amgen, more than either Pfizer or Gilead. Keep in mind that 12.4 million people learn they have cancer each year, while 7.6 million people…

View original post 1,953 more words

Pharmaceutical Industry In Global Market: Issues To Be Handled For Better Growth

New Drug Approvals

In the global market, the position of the pharmaceutical industry is not parallel as compared to other information and technology based industries.
Among the Leading industries, the pharmaceutical industry lacks behind in the growth rate as far as innovative research, capital investment and
government regulations are concern. Most of the countries simply depends on bulk production of the generic drugs and not focused on core research. In
comparison with the growth rate of the electronic and IT industry stands first where as the pharmaceutical comes at the 9th position.

read all at

http://www.pharmainfo.net/reviews/pharmaceutical-industry-global-market-issues-be-handled-better-growth

View original post